Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Aug 31;50(4):474-81.
doi: 10.3349/ymj.2009.50.4.474. Epub 2009 Aug 19.

Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures

Jun Iwamoto  1 , Yoshihiro Sato, Mitsuyoshi Uzawa, Tsuyoshi Takeda, Hideo Matsumoto
Affiliations
Randomized Controlled Trial

Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures

Jun Iwamoto et al. Yonsei Med J. .

Abstract

Purpose: The comparative effects of alendronate and alfacalcidol on bone mineral density (BMD) and bone turnover have already been established in postmenopausal women with osteoporosis. An open-labeled prospective study was conducted to compare the treatment effects of alendronate and alfacalcidol on hip BMD and bone turnover in Japanese men with osteoporosis or osteopenia with clinical risk factors for fractures.

Materials and methods: One hundred twelve men with osteoporosis or osteopenia with clinical risk factors for fractures (mean age: 71.4 years) were randomly divided into two groups of 56 patients each: the alendronate (5 mg daily) and alfacalcidol (1 microg daily) groups. The BMD of the total hip, urinary level of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of bone-specific alkaline phosphatase (BSAP) were measured during the 12-month-treatment period.

Results: Forty-five patients in the alendronate group and 42 patients in the alfacalcidol group completed the trial. Alendronate increased BMD (+2.3% at 12 months) following reductions in the urinary level of NTX (-46.4% at 3 months) and serum level of BSAP (-34.1% at 12 months), while alfacalcidol sustained BMD (-1.9% at 12 months) as well as the urinary level of NTX (+13.2% at 3 months) and serum level of BSAP (+1.8% at 12 months).

Conclusion: The present study confirmed that alendronate has better efficacy than alfacalcidol (active control) in increasing hip BMD and reducing bone turnover in Japanese men with osteoporosis or osteopenia with clinical risk factors for fractures.

Keywords: Alendronate; alfacalcidol; fracture risk; men; osteopenia; osteoporosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflicts of interest.

Figures

Fig. 1
Fig. 1
Percent changes in serum calcium, phosphorus, BSAP and PTH. Data are expressed as the mean ± SE. The serum level of BSAP significantly decreased, but the serum levels of calcium, phosphorus, and intact PTH did not significantly change in the alendronate group (one-way ANOVA with repeated measurements, Table 2). The serum level of calcium significantly increased, but the serum levels of phosphorus, BSAP, and intact PTH did not significantly change in the alfacalcidol group (one-way ANOVA with repeated measurements, Table 2). There were significant differences in changes in the serum levels of calcium and BSAP between the two groups (two-way ANOVA with repeated measurements, Table 2). n = 45 in the alendronate group and n = 42 in the alfacalcidol group. BSAP, bone-specific alkaline phosphatase; PTH, parathyroid hormone.
Fig. 2
Fig. 2
Percent changes in total hip BMD. Data are expressed as the mean ± SE. The BMD significantly increased, but did not significantly change in the alfacalcidol group (one-way ANOVA with repeated measurements, Table 2). There was a significant difference in changes in the BMD between the two groups (two-way ANOVA with repeated measurements, Table 2). n = 45 in the alendronate group and n = 2 in the alfacalcidol group. BMD, bone mineral density.
See this image and copyright information in PMC

References

    1. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437–1443. - PubMed
    1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541. - PubMed
    1. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082. - PubMed
    1. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–1199. - PubMed
    1. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–2938. - PubMed

Publication types

MeSH terms